Stock Market Reviews

MIRM (Mirum Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on MIRM (Mirum Pharmaceuticals, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy?
  CRMD and MIRM are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
  Jan 20, 2026 - $MIRM
• Mirum Stock Rises 7% in a Week: Here's What You Should Know
  MIRM shares rise this week on strong preliminary 2025 sales, upbeat 2026 outlook, key pipeline goals and business updates.
  Jan 16, 2026 - $MIRM
• 3 Top Growth Stocks to Buy in the First Half of 2026
  Don't wait too long to make a decision on these three stocks.
  Jan 13, 2026 - $MIRM
• Assessing Mirum Pharmaceuticals (MIRM) Valuation After Strong Recent Share Price Momentum
  Mirum Pharmaceuticals (MIRM) has been drawing investor attention after a period of strong share price moves, with the stock up around 17% over the past week and about 38% over the past month. See our latest analysis for Mirum Pharmaceuticals. That strong recent momentum sits on top of a longer run of gains, with Mirum showing a 14.6% year to date share price return and a very large 3 year total shareholder return that is around 4x. If this kind of move in rare disease pharma appeals to you,...
  Jan 13, 2026 - $MIRM
• Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026
  Focused on rare liver disease therapies, this biopharma company reported a significant insider sale amid strong one-year stock gains.
  Jan 12, 2026 - $MIRM
• Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  FOSTER CITY, Calif., January 12, 2026--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  Jan 12, 2026 - $MIRM
• Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
  FOSTER CITY, Calif., January 12, 2026--Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
  Jan 12, 2026 - $MIRM
• Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals
  ESCONDIDO, Calif., January 09, 2026--Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and neurodevelopmental disorders, announced that its licensing partner for MRM-3379 (formerly ENT-3379), Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), in December, reported the initiation of the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome (FXS).
  Jan 9, 2026 - $MIRM
• How Investors May Respond To Mirum Pharmaceuticals (MIRM) Expanding Livmarli And Gaining J.P. Morgan Spotlight
  In late 2025, TimesSquare Capital Management added Mirum Pharmaceuticals to its U.S. Small Cap Growth Strategy as the company expanded its flagship liver disease therapy Livmarli toward a third indication and reported very large year-over-year revenue growth in the third quarter. Separately, Mirum disclosed it would present at the J.P. Morgan Healthcare Conference in January 2026, a platform that can showcase its rare disease portfolio and pipeline to a broad institutional audience,...
  Jan 8, 2026 - $MIRM
• Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
  FOSTER CITY, Calif., January 07, 2026--Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
  Jan 7, 2026 - $MIRM